{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:02Z","timestamp":1792118702272,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04085-9","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:58:53Z","timestamp":1779677933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cOndansetron augmentation for obsessive\u2013compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials\u201d"],"prefix":"10.1007","volume":"82","author":[{"given":"Anas","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeq Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Aijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hassnain","family":"Nasrullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"1","key":"4085_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15(1):53\u201363. https:\/\/doi.org\/10.1038\/mp.2008.94","journal-title":"Mol Psychiatry"},{"key":"#cr-split#-4085_CR2.1","unstructured":"National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) [Internet]. London: NICE (2005) [last reviewed 2024"},{"key":"#cr-split#-4085_CR2.2","unstructured":"cited 2026 Feb 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg31"},{"issue":"4","key":"4085_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/YIC.0000000000000314","volume":"35","author":"NA Fineberg","year":"2020","unstructured":"Fineberg NA, Hollander E, Pallanti S et al (2020) Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol 35(4):173\u2013193. https:\/\/doi.org\/10.1097\/YIC.0000000000000314","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"4085_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1176\/appi.ps.54.8.1111","volume":"54","author":"A Kaplan","year":"2003","unstructured":"Kaplan A, Hollander E (2003) A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 54(8):1111\u20131118. https:\/\/doi.org\/10.1176\/appi.ps.54.8.1111","journal-title":"Psychiatr Serv"},{"issue":"3","key":"4085_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"M Dold","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 16(3):557\u2013574. https:\/\/doi.org\/10.1017\/S1461145712000740","journal-title":"Int J Neuropsychopharmacol"},{"key":"4085_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152352","volume":"120","author":"PJ van Roessel","year":"2023","unstructured":"van Roessel PJ, Grassi G, Aboujaoude EN, Mench\u00f3n JM, Van Ameringen M, Rodr\u00edguez CI (2023) Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry 120:152352. https:\/\/doi.org\/10.1016\/j.comppsych.2022.152352","journal-title":"Compr Psychiatry"},{"issue":"3","key":"4085_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pharmthera.2011.02.003","volume":"130","author":"TK Machu","year":"2011","unstructured":"Machu TK (2011) Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther 130(3):338\u2013347. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.02.003","journal-title":"Pharmacol Ther"},{"issue":"28","key":"4085_CR8","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.2174\/138161206778522029","volume":"12","author":"AJ Thompson","year":"2006","unstructured":"Thompson AJ, Lummis SCR (2006) 5-HT3 receptors. Curr Pharm Des 12(28):3615\u20133630. https:\/\/doi.org\/10.2174\/138161206778522029","journal-title":"Curr Pharm Des"},{"issue":"6","key":"4085_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3000","volume":"13","author":"B Jalal","year":"2023","unstructured":"Jalal B, Chamberlain SR, Sahakian BJ (2023) Obsessive-compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain Behav 13(6):e3000. https:\/\/doi.org\/10.1002\/brb3.3000","journal-title":"Brain Behav"},{"issue":"6","key":"4085_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/hup.1145","volume":"25","author":"F Soltani","year":"2010","unstructured":"Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I (2010) A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 25(6):509\u2013513. https:\/\/doi.org\/10.1002\/hup.1145","journal-title":"Hum Psychopharmacol"},{"key":"4085_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4085_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"3","key":"4085_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"7414","key":"4085_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"4085_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range, and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"4085_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4085_CR17","volume-title":"[Computer program]. Version 5.4","author":"Review Manager (RevMan)","year":"2020","unstructured":"Review Manager (RevMan) (2020) [Computer program]. Version 5.4. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen"},{"issue":"6","key":"4085_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","volume":"29","author":"M Heidari","year":"2014","unstructured":"Heidari M, Zarei M, Hosseini SMR, Taghvaei R, Maleki H, Tabrizi M et al (2014) Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol 29(6):344\u2013350. https:\/\/doi.org\/10.1097\/YIC.0000000000000043","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"4085_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/YIC.0000000000000267","volume":"34","author":"M Sharafkhah","year":"2019","unstructured":"Sharafkhah M, Aghakarim Alamdar M, Massoudifar A, Abdolrazaghnejad A, Ebrahimi-Monfared M, Saber R et al (2019) Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol 34(5):222\u2013233. https:\/\/doi.org\/10.1097\/YIC.0000000000000267","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"4085_CR20","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.100918","volume":"22","author":"Z Sepehrmanesh","year":"2020","unstructured":"Sepehrmanesh Z, Adel M, Ahmadvand A, Sehat M (2020) Ondansetron augmentation for treatment-resistant obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. Iran Red Crescent Med J 22(5):e100918. https:\/\/doi.org\/10.5812\/ircmj.100918","journal-title":"Iran Red Crescent Med J"},{"key":"4085_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4103\/kleuhsj.kleuhsj_29_21","volume":"14","author":"J Ahmad","year":"2021","unstructured":"Ahmad J, Nischal A, Nischal A, Gupta B, Agarwal M, Tripathi A (2021) Ondansetron in combination with fluoxetine for obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study from North India. Indian J Health Sci Biomed Res 14:356\u2013364. https:\/\/doi.org\/10.4103\/kleuhsj.kleuhsj_29_21","journal-title":"Indian J Health Sci Biomed Res"},{"issue":"3","key":"4085_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1176\/appi.ajp.20240294","volume":"182","author":"ER Stern","year":"2025","unstructured":"Stern ER, Collins KA, Bragdon LB, Eng GK, Recchia N, Coffey BJ et al (2025) Randomized controlled trial of the effects of high-dose ondansetron on clinical symptoms and brain connectivity in obsessive-compulsive and tic disorders. Am J Psychiatry 182(3):285\u2013296. https:\/\/doi.org\/10.1176\/appi.ajp.20240294","journal-title":"Am J Psychiatry"},{"issue":"1","key":"4085_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/wps.20299","volume":"15","author":"D Mataix-Cols","year":"2016","unstructured":"Mataix-Cols D, Fern\u00e1ndez de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB (2016) Towards an international expert consensus for defining treatment response, remission, recovery, and relapse in obsessive-compulsive disorder. World Psychiatry 15(1):80\u201381. https:\/\/doi.org\/10.1002\/wps.20299","journal-title":"World Psychiatry"},{"key":"4085_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jpsychires.2023.10.029","volume":"167","author":"S Hamanaka","year":"2023","unstructured":"Hamanaka S, Kishi T, Sakuma K, Nishii Y, Hatano M, Iwata N (2023) Serotonin 3 receptor antagonists for obsessive-compulsive disorder: a systematic review and pairwise meta-analysis. J Psychiatr Res 167:132\u2013138. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.10.029","journal-title":"J Psychiatr Res"},{"issue":"2","key":"4085_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2001.tb00195.x","volume":"7","author":"JH Ye","year":"2001","unstructured":"Ye JH, Ponnudurai R, Schaefer R (2001) Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 7(2):199\u2013213. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00195.x","journal-title":"CNS Drug Rev"},{"issue":"1","key":"4085_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47931-x","volume":"13","author":"N Eissazade","year":"2023","unstructured":"Eissazade N, Mosavari H, Eghdami S, Boroon M, Ashrafi F, Shalbafan M (2023) Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with SSRIs in moderate to severe OCD: a systematic review and meta-analysis of randomized clinical trials. Sci Rep 13(1):20837. https:\/\/doi.org\/10.1038\/s41598-023-47931-x","journal-title":"Sci Rep"},{"issue":"8","key":"4085_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","volume":"3","author":"P Skapinakis","year":"2016","unstructured":"Skapinakis P, Caldwell DM, Hollingworth W et al (2016) Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 3(8):730\u2013739. https:\/\/doi.org\/10.1016\/S2215-0366(16)30069-4","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"4085_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/acps.13568","volume":"148","author":"R Maiti","year":"2023","unstructured":"Maiti R, Mishra A, Srinivasan A, Mishra BR (2023) Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: a network meta-analysis. Acta Psychiatr Scand 148(1):19\u201331. https:\/\/doi.org\/10.1111\/acps.13568","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"4085_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1124\/pr.118.015487","volume":"71","author":"G Fakhfouri","year":"2019","unstructured":"Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, Zirak MR, Beaulieu JM (2019) 5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface. Pharmacol Rev 71(3):383\u2013412. https:\/\/doi.org\/10.1124\/pr.118.015487","journal-title":"Pharmacol Rev"},{"issue":"3","key":"4085_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.neubiorev.2007.09.005","volume":"32","author":"L Menzies","year":"2008","unstructured":"Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET (2008) Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32(3):525\u2013549. https:\/\/doi.org\/10.1016\/j.neubiorev.2007.09.005","journal-title":"Neurosci Biobehav Rev"},{"issue":"Suppl 3","key":"4085_CR31","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/S0924-977X(99)00030-9","volume":"9","author":"DJ Nutt","year":"1999","unstructured":"Nutt DJ, Forshall S, Bell C et al (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9(Suppl 3):S81\u2013S86. https:\/\/doi.org\/10.1016\/S0924-977X(99)00030-9","journal-title":"Eur Neuropsychopharmacol"},{"key":"4085_CR32","unstructured":"US Food and Drug Administration (FDA) (2012) FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products [Internet]. Silver Spring (MD): FDA; 2012 Dec 4 [content current as of 2016; cited 2026 Feb 12]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-information-32-mg-intravenous-ondansetron-zofran-dose-and-pre"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04085-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:16:53Z","timestamp":1781072213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04085-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4085"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04085-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published studies. It does not involve any direct participation of human subjects, collection of identifiable personal data, or intervention. Therefore, ethical approval and consent to participate were not required for this study in accordance with institutional and international research guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Since this work is a systematic evaluation of already published research, informed consent and institutional review board approval were not necessary, and no additional human or animal participants were enlisted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical conduct of research"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}